Why not treat human cancer with interleukin-1 blockade?

The clinical successes of targeting angiogenesis provide a basis for trials of interleukin-1 (IL-1) blockade and particularly anti-IL-1β as an add-on therapy in human metastatic disease. In animal studies for over 20 years, IL-1 has been demonstrated to increase adherence of tumor cells to the endot...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Cancer and metastasis reviews 2010-06, Vol.29 (2), p.317-329
1. Verfasser:	Dinarello, Charles A.
Format:	Artikel
Sprache:	eng
Schlagworte:	Angiogenesis Inhibitors - therapeutic use Animals Antineoplastic Agents - therapeutic use Antirheumatic Agents - therapeutic use Arthritis, Rheumatoid - drug therapy Biomedical and Life Sciences Biomedicine Cancer Cancer Research Endothelium Humans Interleukin 1 Receptor Antagonist Protein - metabolism Interleukin 1 Receptor Antagonist Protein - therapeutic use Interleukin-1 - antagonists & inhibitors Interleukins Medical research Medicine, Experimental Metastasis Monoclonal antibodies Neoplasms - blood supply Neoplasms - drug therapy Neovascularization Neovascularization, Pathologic - drug therapy Oncology Rheumatoid factor
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!